Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | F13A1 | P00488 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | ESRRG | P62508 | 3/20 | 0.56 |
| ▸ | ESRRB | O95718 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439339 | 0.98 | CA2 (0.58) | KDM4EF13A1NQO2CA2CA1 | |
| SCHEMBL4449400 | 0.93 | KDM4E (0.53) | KDM4EF13A1NQO2CA2CA1 | |
| SCHEMBL13892876 | 0.93 | NAMPT (0.56) | KDM4EF13A1NQO2CA2CA1 | |
| SCHEMBL7465537 | 0.91 | ESRRG (0.58) | KDM4EF13A1NQO2CA2CA1 | |
| SCHEMBL917871 | 0.89 | TDP1 (0.54) | KDM4EF13A1NQO2CA2CA1 | |
| SCHEMBL7272921 | 0.88 | TDP1 (0.56) | NQO2CA2CA1ESRRGSIGMAR1 | |
| SCHEMBL972688 | 0.88 | KDM4E (0.54) | KDM4EF13A1NQO2CA2CA1 | |
| SCHEMBL1569661 | 0.87 | CA2 (0.56) | NQO2CA2CA1NAMPTCTSK | |
| SCHEMBL12283041 | 0.87 | NPC1 (0.60) | NQO2CA2CA1NAMPTMAPT | |
| SCHEMBL27741035 | 0.87 | CA2 (0.56) | NQO2CA2CA1NAMPTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107430355-B | Coating liquid for coating resist pattern and pattern forming method | 日产化学工业株式会社 | 2023-07-14 | — | — | CN | claimed |
| CN-113908290-B | Multifunctional nano-composite and preparation method and application thereof | 山东大学 | 2023-06-02 | — | — | CN | claimed |
| CN-113105424-B | Bactericidal compound based on exogenous metabolites of xanthomonas as well as preparation method and application of bactericidal compound | 华中农业大学 | 2022-06-07 | — | — | CN | claimed |
| CN-113105424-A | Bactericidal compound based on exogenous metabolites of xanthomonas as well as preparation method and application of bactericidal compound | 华中农业大学 | 2021-07-13 | — | — | CN | claimed |
| US-10613435-B2 | Coating solution for resist pattern coating and method for forming pattern | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2020-04-07 | — | — | US | claimed |
| JP-4233937-A | — | — | None | — | — | JP | disclosed |
| US-20260115334-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115333-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-3492919-B1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2025-06-19 | — | — | US | disclosed |
| EP-0641770-A1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993010074-A1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS BETA-3-ADRENOCEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-05-27 | — | — | WO | disclosed |
| JP-H04233937-A | BLOCKED AMINE TERMINATED POLYCARBONATE | GENERAL ELECTRIC CO <GE> | 1992-08-21 | — | — | JP | disclosed |
| EP-0483667-A2 | Cyclic imino derivatives, process for their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0469447-A2 | Blocked amine terminated polycarbonates and products obtained thereof | GENERAL ELECTRIC COMPANY (US) | 1992-02-05 | — | — | EP | disclosed |
| EP-0469447-A2 | Blocked amine terminated polycarbonates and products obtained thereof | GENERAL ELECTRIC COMPANY (US) | 1992-02-05 | — | — | EP | disclosed |
| US-5068284-A | To improve solvent resistance in modified polymers | GENERAL ELECTRIC COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
| US-5068284-A | To improve solvent resistance in modified polymers | GENERAL ELECTRIC COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115334-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | FGF23, FOLH1, HDGF | KDM4E 2035/4885F13A1 35/4885NQO2 4145/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | KDM4E 1204/4885F13A1 188/4885NQO2 1808/4885 |
| US-20260115333-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | FGF23, SLC34A2, SLC34A3 | KDM4E 3700/4885F13A1 53/4885NQO2 4061/4885 |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | KDM4E 2284/4885F13A1 4107/4885NQO2 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.